drugset / Trial / NCT00744731

An Open-Label Extension Study of the Safety and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset Seizures

NCT00744731

Phase 3 Completed 403 enrolled SK Life Science, Inc.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to obtain long-term safety and tolerability information on carisbamate as add-on therapy for the treatment of partial onset seizures in patients with epilepsy. Seizure counts will be obtained to measure the rate of seizures for each patient during the study.

Timeline

Start
2009-01
Primary completion
2010-08
Completion
2010-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Carisbamate Small molecule 800 mg Oral